MARKET

BBI

BBI

Brickell Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
0.000
0.00%
After Hours: 1.100 0 0.00% 17:53 01/15 EST
OPEN
1.100
PREV CLOSE
1.100
HIGH
1.120
LOW
1.050
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
3.980
52 WEEK LOW
0.4660
MARKET CAP
58.87M
P/E (TTM)
-0.4574
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CLSK, ISR, SYN and BBI among midday movers
Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Energy Technology (CBAT) +28%.Losers: IMARA (IMRA) -35%.Second Sight Medical Products (EYES) -23%.Mexco
Seekingalpha · 01/06 17:47
Isoray, Guardion Health Sciences leads healthcare gainers; IMARA, Synthetic Biologics among major losers
Gainers: Isoray (ISR) +181%, Guardion Health Sciences (GHSI) +57%, AIkido Pharma AIKI +57%, Orchard Therapeutics ORTX +41%, Change Healthcare CHNG +31%.Losers: IMARA IMRA -35%, Synthetic Biologics (SYN) -25%, Second Sight Medical Products (EYES) -22%, Atossa Therapeutics ATOS -21%, Brickell Biotech (BBI) -10%.
Seekingalpha · 01/06 16:01
Bionano Genomics, Clearside Biomedical among major healthcare premarket losers' pack
My Size (MYSZ) -21% after pricing equity offering.Titan Medical (TMDI) -18% after announcing $10M bought deal offering.Synthetic Biologics (SYN) -16%.Brickell Biotech (BBI) -10%.Bionano Genomics (BNGO) -8%.Marker Therapeutics (MRKR) -7%.Clearside Biomedical (CLSD) -6% on launch of $12M direct
Seekingalpha · 01/06 13:13
Reflecting on Brickell Biotech's (NASDAQ:BBI) Share Price Returns Over The Last Year
Brickell Biotech, Inc. ( NASDAQ:BBI ) shareholders will doubtless be very grateful to see the share price up 75% in the...
Simply Wall St. · 01/06 05:50
Brickell Biotech Doses First Patient In Second US Pivotal Phase 3 Clinical Study Evaluating ECCLOCK
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK®) recently launched in Japan by
Benzinga · 12/07/2020 12:31
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK®) recently launched in Japan by development partner, Kaken PharmaceuticalBOULDER, Colo., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced dosing of the first patient in its second U.S. pivotal Phase 3 clinical study (“Cardigan II study”) evaluating sofpironium bromide gel, 15% in approximately 350 subjects aged nine and older with primary axillary (underarm) hyperhidrosis. Brickell’s U.S. Phase 3 program is comprised of two pivotal trials, the Cardigan I and Cardigan II studies, which are both currently enrolling patients. The Company expects to announce topline results from these two studies in the fourth quarter of 2021. If successful, the results from the studies are expected to form the basis of a prospective New Drug Application in the U.S. for sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis. Additional details of the Cardigan II study can be found on https://clinicaltrials.gov under identifier NCT03948646.“We are excited to announce the initiation of the Cardigan II study, which is the second trial in our U.S. pivotal Phase 3 clinical program for sofpironium bromide gel, 15%,” said Deepak Chadha, Chief Research and Development Officer of Brickell. “This marks another important milestone for the Company, and we continue to be encouraged by the progress we are making with our Phase 3 program, particularly in light of the current environment. We look forward to providing enrollment updates for the Cardigan I and II studies in the coming months.”On November 26, 2020, Brickell’s Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) launched commercial sales of ECCLOCK® in Japan for the once-daily treatment of primary axillary hyperhidrosis. This marks the first commercialization of sofpironium bromide worldwide. Under the sublicense agreement with Kaken, Brickell is entitled to receive sales-based milestone payments, as well as tiered royalties based on a percentage of net sales of sofpironium bromide gel in Japan. Furthermore, Kaken has rights to develop and commercialize sofpironium bromide in South Korea, China, and certain other Asian countries, and Brickell is entitled to receive royalties based on a percentage of Kaken’s net sales in these countries.About Sofpironium BromideSofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action locally and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design, progress and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory submissions and approvals, and prospects for commercializing any of Brickell’s product candidates, or research collaborations with, or actions of, its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
GlobeNewswire · 12/07/2020 12:30
Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Brickell Biotech's (BBI) Japanese development partner, Kaken Pharmaceutical plans to launch sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the once daily treatment of primary axillary
Seekingalpha · 11/18/2020 13:04
Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical
Kaken plans to launch ECCLOCK® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 \- - - ECCLOCK® placed on Japan’s National Health Insurance (NHI) drug reimbursement price listBOULDER, Colo., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) plans to launch sofpironium bromide gel, 5% under the brand name ECCLOCK® in Japan for the once daily treatment of primary axillary (underarm) hyperhidrosis on November 26, 2020. In addition, ECCLOCK® has been placed today on Japan’s National Health Insurance (NHI) drug reimbursement price list. The NHI listed drug price for ECCLOCK® in Japan is ¥243.70 per gram, which is ¥4,874.00 (USD $46.47) for a 20 gram bottle or approximately a two-week supply.“We are excited to announce the reimbursement and planned commercial launch of ECCLOCK® in Japan, which is the first topical prescription product to be approved and marketed there for the treatment of primary axillary hyperhidrosis,” said Robert Brown, Chief Executive Officer of Brickell. “A key step to Kaken’s moving forward with the planned commercial launch of ECCLOCK® in Japan was their receipt of the reimbursement price listing by the NHI. Kaken is now well-positioned to launch ECCLOCK® in Japan on November 26 as an important novel, first-in-class therapy for the millions of Japanese patients suffering with this debilitating medical condition.”On September 25, 2020, Kaken received approval from the Japanese Pharmaceuticals and Medical Devices Agency to manufacture and market ECCLOCK® for the once-daily treatment of primary axillary hyperhidrosis.Under the sublicense agreement with Kaken, Brickell is entitled to receive sales-based milestone payments, as well as tiered royalties based on a percentage of net sales of ECCLOCK® in Japan. Furthermore, Kaken has rights to develop and commercialize sofpironium bromide in Korea, China and certain other Asian countries.Sofpironium bromide is currently being developed by Brickell in the U.S. for the treatment of primary axillary hyperhidrosis. Brickell recently initiated its pivotal Phase 3 clinical program in the U.S., which is comprised of two pivotal Phase 3 clinical trials (Cardigan I and II) to evaluate the safety and efficacy of sofpironium bromide gel, 15% compared to vehicle (placebo) in approximately 350 subjects (per trial) aged nine years and older with primary axillary hyperhidrosis. Brickell expects to report topline data from both the Cardigan I and II studies in the fourth quarter of 2021.About Sofpironium BromideSofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood.  Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with, or actions of, its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, AnGes or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply, launch and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.                                  1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
GlobeNewswire · 11/18/2020 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BBI. Analyze the recent business situations of Brickell Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BBI stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 3.74M
% Owned: 6.98%
Shares Outstanding: 53.52M
TypeInstitutionsShares
Increased
3
414.36K
New
12
-910.00K
Decreased
2
1.37K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Co-Founder/Director
Reginald Hardy
Chief Executive Officer/Director
Robert Brown
Co-Founder/Chief Operating Officer/Secretary
Andrew Sklawer
Chief Financial Officer
R. Carruthers
Chief Financial Officer
Albert Marchio
Chief Accounting Officer/Controller
Jose Breton
Chief Compliance Officer/General Counsel/Secretary
David McAvoy
Other
Deepak Chadha
Other
Adam Levy
Director
Gary Lyons
Director
Vijay Samant
Director
Dennison Veru
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BBI
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Brickell Biotech Inc stock information, including NASDAQ:BBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BBI stock methods without spending real money on the virtual paper trading platform.